CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera isviewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF).

Biotechnology

Health Care

CellProthera

CellProthera's headquarters in Mulhouse, France

Description

People

Jobs